PF-Atlas › Clinical Trials › NCT05671835

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

TTI-101 · Phase 2

Registry ID

NCT05671835

Phase

Phase 2

Status

Completed

Drug / intervention

TTI-101

Sponsor

Tvardi Therapeutics, Incorporated

Start

2023-05-15

Enrollment

100

Locations

About this trial

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

View NCT05671835 on ClinicalTrials.gov →

Explore related

All TTI-101 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05671835 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.